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Further randomized studies are needed … is arguably
the most frequent conclusion of publications in the
field of oncological surgery and most of the time also
a hopeless prayer. High-level evidence is indeed always
welcome. However, it is a tremendous challenge to
conduct randomized controlled trials (RCT) in cancer
surgery. Heterogeneity of patients and treatments, dif-
ficult blinding, and modest sample size are just some
out of many methodological shortcomings frequently
encountered in surgical RCTs. Moreover, it is difficult
to fund RCTs in surgical oncology since there is usually
no major industrial support, in contrast to medical
oncology. Last but not least, if the available evidence
suggests a much worse outcome for the control arm vs.
the experimental surgical arm, it can be very challen-
ging or even impossible to recruit enough patients for a
randomized trial.
Therefore, it is all but a surprise that most current
practice in surgery is not supported by level-I evidence.
Prominent examples are laparoscopic vs. open cholecys-
tectomy, hepatectomy for liver metastases, cytoreductive
surgery (CRS) in ovarian cancer and the Whipple’s proce-
dure in pancreatic cancer – as compared to systemic
palliative chemotherapy. This has led some authors to
ignore all evidence except double-blinded RCTs and to
compare surgical research with a comic opera [1] – which
might appear inappropriate considering the challenges
above. Prominent authors suggest therefore that large-
scale prospective multicenter data might fill the evidence
gap in surgical oncology research [2]. But still, only high-
quality evidence – ideally in the form of RCTs – will
persuade the different stakeholders to accept a novel
treatment and the health insurances to pay for it [3].
CRS and Hyperthermic IntraPEritoneal Chemotherapy
(HIPEC) might serve as an example for the difficulties
encountered in evidencing an innovative surgical proce-
dure. The concept of CRS and HIPEC is more than
30 years old, but results from the first RCT were reported
only after 15 years: a Dutch multicenter study showed a
significant survival benefit for patients with isolated peri-
toneal metastasis of colorectal origin who received CRS
and HIPEC in addition to systemic chemotherapy as com-
pared to chemotherapy alone [4]. This study was heavily
criticized already at the time of publication, as mean-
while systemic treatment options had evolved consider-
ably. Indeed, survival rates for patients with stage IV
disease treated with modern combination chemotherapy
now exceed survival of the experimental arm in the Dutch
trial [5]. However, the randomized data were confirmed
by several large prospective studies showing superior
survival figures for patients with isolated peritoneal
metastasis of colorectal origin treated with CRS and
HIPEC [2, 6, 7]. Thirteen years after the Dutch trial, in
2016, CRS and HIPEC was recommended for the first time
in the ESMO guidelines for selected patients with perito-
neal metastasis of colorectal origin [8]. Presented at the
ASCO meeting 2018 [9], results from the French PRODIGE
7 randomized controlled trial are now challenging this
recommendation again. The PRODIGE 7 trial is a French
multicenter RCT, where 267 patients with peritoneal
metastases (PCI < 25) were randomized to receive either
CRS and HIPEC (oxaliplatin) or CRS alone in conjunction
with systemic chemotherapy. No significant difference
was found between the groups in terms of overall and
disease-free survival, but 60 day major morbidity was
higher in the HIPEC group. During the same meeting,
results of the French PROPHYLOCHIP trial were
presented, showing peritoneal metastasis in 52% of
CT-negative patients and underlining the rationale for a
second look strategy in these patients. However, prophy-
lactic HIPEC added no benefit in terms of peritoneal
relapse and overall survival at 3 years compared to sur-
veillance alone. Thus, books are not closed for HIPEC for
colorectal peritoneal metastasis and current recommen-
dations might need to be revised.
Ironically, the image in ovarian cancer is like a nega-
tive of the picture obtained in colorectal cancer. In ovar-
ian cancer, despite strong evidence showing superior
outcomes of intraperitoneal chemotherapy in addition to
systemic chemotherapy in three randomized trials [10],
HIPEC failed to reach large acceptance among gynecolo-
gical surgeons and oncologists. At the end of 2017, a
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Dutch multicenter RCT documented increased overall and
disease-free survival in ovarian cancer patients receiving
CRS+HIPEC as compared to CRS alone [11], providing
unequalled evidence in surgical therapy of ovarian can-
cer. Critics of this study were not long in coming and it is
unclear at this point of time when this evidence level-I
data will be included in therapy guidelines.
Pressurized IntraPeritoneal Aerosol Chemotherapy
(PIPAC) is blowing fresh wind into this hot research
landscape. First used in human in November 2011 [12],
PIPAC is not even 7 years old and several RCTs have
already been initiated. PIPAC technology was first devel-
oped and tested by a single team, including Phase-I [13]
and Phase-II trials, and then carefully spread out to a
handful of academic teams. Technology access was sub-
ject to participation to certification courses, so that cur-
rent international practice is very homogenous in terms
of indications, technique and treatment protocols [14].
The body of evidence is growing rapidly and the current
results encourage further evaluation [15].
What was shown already?
– PIPAC can be safely implemented with minimal
learning curve
– Repetitive PIPAC treatment is feasible and safe
– PIPAC has no negative impact on quality of life and
symptoms
– Short-term oncological outcomes are favorable
What needs to be further
investigated
– Oncological efficacy including long-term outcomes
– Long-term toxicity
– Confirmation of current indications, evaluation of
extended indications
– Transition from empirical to evidence-based therapy
protocols: choice of intraperitoneal drugs and drug
combinations, dose-escalation protocols, duration,
pressure, nebulizer technology; combined vs. sequen-
tial systemic treatment, etc.
As of June 10, at least 15 prospective studies on PIPAC
were registered in public databases (NCT and Eudra-CT),
including an international registry [16]. The protocols of
three of these studies plus two new studies are presented
in this issue of Pleura and Peritoneum.
Two protocols were elaborated by the group from
Odense PIPAC center (OPC). PIPAC-OPC2 [17] is a pro-
spective single center phase II study on treatment
response in peritoneal cancer of different primaries.
Primary outcome is histological response (assessed by
PRGS) after three PIPAC treatments and estimated sample
size is 137 patients. The same group launched a Phase-II
protocol (PIPAC-OPC3) assessing PIPAC as adjuvant treat-
ment in high-risk colon cancer patients after adjuvant
systemic treatment [18]. Primary endpoint is 3 year peri-
toneal disease-free survival as assessed by CT scan. Of
note, this study protocol is very similar to the French
multicenter study PROPHYLOCHIP described above. It
remains to be seen whether PIPAC can top HIPEC due
to its pharmacokinetic advantages (distribution, tissue
penetration, repeated administration).
Two study protocols evaluate a potential beneficial
effect of adding PIPAC with cisplatin and doxorubicin to
systemic chemotherapy. PIPAC EstoK 01 is a French mul-
ticenter randomized phase II study in gastric cancer
patients who are no candidates for CRS and HIPEC
(PCI > 8) [19]. Ninety-four patients shall be equally rando-
mized to receive standard palliative combination che-
motherapy alone (control) or in combination with 3
PIPAC procedures. Progression-free survival is the pri-
mary endpoint. A similar, German study protocol evalu-
ates 3 × PIPAC in combination with FOLFOX vs. FOLFOX
alone in patients with peritoneal seeding from upper GI
tumors [20]. This international multicenter RCT aims at
randomizing 206 patients. Primary endpoint is progres-
sion-free survival. Of note, both study protocols foresee
the conservative empirical drug combination of cisplatin
(7.5mg/m2) in combination with doxorubicin (1.5mg/m2)
and not the new regimen defined by the dose-escalation
study in ovarian cancer patients [2].
Finally, a fifth study protocol presented by the Gent
group is evaluating a nanomolecule administered intra-
peritoneally as PIPAC. This is an international Phase I-II
trial examining the effect of Albumin-stabilized paclitaxel
nanoparticles (AbraxaneTM) in patients with peritoneal
metastasis of various origins [21]. A Bayesian approach
is applied in order to define the dose limiting toxicity as
primary endpoint.
The only true wisdom is in knowing you know nothing,
wrote Socrates 2500 years ago. Yes indeed, little is known
about oncological efficacy of PIPAC at this point of time.
However, it appears that lessons were learnt from the
HIPEC experience and that PIPAC follows the “IDEAL
framework of surgical innovation” [22–24].
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Controlled implementation of PIPAC, a potentially
toxic treatment, is warranted by certification courses
and mentoring programs. Detailed description of techni-
que, safety protocols, standardized perioperative path-
ways and checklists are freely accessible online [25]. Due
to highly standardized therapy protocols [14], serious
scientific evaluation of PIPAC has been started as
reflected by the study protocols in this issue. In addi-
tion, the real world experience outside study protocols is
captured by the international PIPAC registry. It remains
to be awaited whether the PIPAC community is able to
maintain this high standard of controlled implementa-
tion and standardization of treatment protocols with the
rapid spread of this technology.
Yes, PIPAC is on the fast lane but speed limits need
to be respected!
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